Australia - English - Department of Health (Therapeutic Goods Administration)

hospira pty limited - cisatracurium besylate -

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - papaverine hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cisatracurium besylate -

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cisatracurium besilate, quantity: 0.669 % w/v - solution - excipient ingredients: benzenesulfonic acid; water for injections - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cisatracurium besilate, quantity: 0.268 % w/v - solution - excipient ingredients: water for injections; benzenesulfonic acid - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cisatracurium besilate, quantity: 0.268 % w/v - solution - excipient ingredients: benzenesulfonic acid; water for injections - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cisatracurium besilate, quantity: 0.268 % w/v - solution - excipient ingredients: water for injections; benzenesulfonic acid - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - sugammadex 100 mg/ml (as sodium);  ;   - solution for injection - 100 mg/ml - active: sugammadex 100 mg/ml (as sodium)     excipient: hydrochloric acid sodium hydroxide water for injection - bridion is indicated for the reversal of neuromuscular blockade induced by rocuronium or vecuronium in patients 2 years of age and older

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - papaverine hydrochloride 12 mg/ml - solution for injection - 120 mg/10ml - active: papaverine hydrochloride 12 mg/ml excipient: water for injection

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - sugammadex - solution for injection - sugammadex 100 mg/ml - sugammadex - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium.